Rx - AMCo
advertisement
AMCo – new beginnings 20th November 2013 Presenter John Beighton • Medical Rep/Regional Manager - Smith Kline and French UK – • Various sales and marketing jobs – SmithKline Beecham UK – • 2002-2009 VP Global Business Optimisation – Teva Pharmaceutical Ind. – • 1997-2002 Managing Director Teva UK – • 1990-1997 Commercial Director – APS Berk/Teva UK – • 1981-1990 2009 – 2010 CEO AMCo – 2010 to date Company Origins “G word” Mar-12 Oct-12 Aug-12 £367m £465m Jan-13 Refinancing Rebranding Revenues in the United Kingdom 38 Countries with commercial presence Rx ------ ------ ------ 80% ------ million 2012 Sales ------ ------ ------ £106 ------ Established 1991, Headquarters in South London Acquired by Cinven (Private Equity) August 2012 for £465 million ------ ------ 1991 Established Brands and Generics Virtual Business Model (R&D, Manufacturing outsourced) Mercury Pharma ------ 2002 ------ Established 2002, Headquarters East of London. Acquired by Cinven (Private Equity) August 2012 for £367 million ------ £109 million ------ 2012 Sales ------ 34% ------ Revenues in the United Kingdom ------ 100+ ------ Countries with commercial presence ------ Rx ------ Established Brands and Generics Virtual Business Model (R&D, Manufacturing outsourced) Amdipharm million 60% 112 Rx ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ £248 ------ ------ 2013 Combined group rebranded AMCo in March 2013 UK Office to be relocated to Central London 2013 Expected revenues (15% Growth) Revenues in the United Kingdom Countries with commercial presence Established Brands and Generics Virtual Business Model (R&D, Manufacturing outsourced) Amdipharm Mercury (AMCo) Acquisition History Eltroxin levothyroxine £27m 13 Countries Liothyronine Diamox Hytrin Hygroton Ludiomil Cafergot liothyronine £10m 10 Countries acetazolamide £5m 27 Countries terazosin £5m 21 Countries chlortalidone £5m 12 Countries maprotiline £3m 25 Countries ergotamine £2m 26 Countries 1992 2001 1999 Macrodantin, Furadantin, Macrobid, Furabid nitrofurantoin £18m 18 Countries figures quoted are 2013 forecast revenues 2006 2004 2008 2007 2013 Neomercazole Erythrocin Akineton Transact Fucithalmic carbimazole £12m 20 Countries erythromicin £16m 32 Countries biperiden £7m 21 Countries flurbiprofen £8m 2 Countries fusidic acid £26m >90 Countries Management Team John Beighton CEO Peter van Tiggelen CFO Robert Sully General Counsel Bharat Karbal Medical & Regulatory Brian McEwan Managing Director Amdipharm Guy Clark Strategic Development John Cowell Human Resources Vikram Kamath Finance Director Simon Tucker International Commercial Karl Belk Global Operations Jane Hill UK Commercial Company Performance Sales History by Company 2010 £79 £125 2010 to 2013 est. 2011 £88 2012 £113 £106 2013 £109 £126 £0 £50 £122 £100 Mercury £150 Amdipharm £200 £250 Millions Top 10 Molecules (Percentage of 2012 revenue) Levothyroxine 11% Erythromicin 8% Nitrofurantoin 7% Flurbiprofen 5% Codeine + paracetamol 5% Biperiden 4% Liothyronine 4% Carbimazole 4% Prednisolone 4% Cyclizine 3% AMCo Strategy • Consolidate strong position in UK – Off-patent brands and niche products UK Commercial Team Jane Hill UK Commercial Director Jeremy Devaney Hospitals Jenna Pritchard National Accounts Neil Cook Promoted Products AMCo Strategy • Focus on 5 Business Action Plans – Operational Excellence – Culture and Integration – Compliance – Quality and Reputation – International Excellence – Strategic Growth Global Coverage >50% of sales in UK AMCo offices/direct presence Distributor network International Excellence AMCo offices/direct presence Distributor network Target markets – direct presence Strategic Growth Licensing Development Acquisition Dedicated business development team focused on driving revenue and profit growth Brands Primary & Secondary Care •Low Competition •Stable Revenues and Profit •Multiple Markets •Growth Opportunities Therapeutic Focus Primary & Secondary Care •Ophthalmology •Endocrinology •Urology •Infectious Diseases •Pain & Anaesthesia Geographic Expansion Generics Companies & Products Primary & Secondary Care •Company acquisitions •Build out in Target Markets •Portfolio Optimisation •Distributor consolidation •Low Competition •Barriers to Entry •Branded Generics •Sustainable Pricing Strategic Development Activity • Portfolio Optimisation – registering existing AMCo products into new markets where the product isn’t currently registered or sold, and using the existing manufacturers to make the product • Product Development – creating new products with a contract development partner, whereby AMCo retains full ownership rights to the product, and freedom to choose who to manufacture the product • In-Licensing – buying the rights to sell a third party’s product in a defined territory, and agreeing for the licensor to supply the product to AMCo for an agreed period of time (typically 5 years) • Product Acquisitions – buying the permanent rights to own an existing product, in a defined territory (sometimes global e.g. Fucithalmic). The seller may wish to continue making the product, but more often would require AMCo to find a new supplier within 2-3 years United Kingdom Ireland India No. 1 Croydon 12-16 Addiscombe Road Croydon CR0 0XT 102 Block B The Crescent Building Northwood Santry Dublin 9 101 Vedanta 779 Makwana Road Marol Andheri East Mumbai 400 059 +353 (0)1 6971640 +91 22 6678 4444 +44 (0)20 8649 8500 www.amcolimited.com Committed to being a socially responsible company, we support:
